Statement of Principles concerning benign neoplasm of the eye and adnexa No. 33 of 2008 (Cth)
Statement of Principles
concerning
BENIGN NEOPLASM OF THE EYE AND ADNEXA
Instrument No. 33 of 2008 as amended
made under section 196B(2) of the
Veterans’ Entitlements Act 1986
This compilation was prepared on 27 July 2011 taking into account Amendment of Statement of Principles concerning BENIGN NEOPLASM OF THE EYE AND ADNEXA (Instrument No. 75 of 2011)
Prepared by the Repatriation Medical Authority Secretariat, Brisbane
Statement of Principles
concerning
BENIGN NEOPLASM OF THE EYE AND ADNEXA
No. 33 of 2008
for the purposes of the
Veterans’ Entitlements Act 1986
and
Military Rehabilitation and Compensation Act 2004
Title
This Instrument may be cited as Statement of Principles concerning benign neoplasm of the eye and adnexa No. 33 of 2008.
Determination
The Repatriation Medical Authority under subsection 196B(2) and (8) of the Veterans’ Entitlements Act 1986 (the VEA):
(a) revokes Instrument No. 182 of 1995 concerning benign neoplasm of the eye; and
(b) determines in its place this Statement of Principles.
Kind of injury, disease or death
(a) This Statement of Principles is about benign neoplasm of the eye and adnexa and death from benign neoplasm of the eye and adnexa.
(b)For the purposes of this Statement of Principles, "benign neoplasm of the eye and adnexa" means a non-malignant neoplastic proliferation of the cells of the eye classified according to site as conjunctiva, cornea, retina, choroid, ciliary body, lacrimal gland, lacrimal duct and orbit. This definition excludes benign neoplasms of eyelids, optic nerve, meninges, orbital bone, lipoma, haemangioma, lymphangioma, melanocytic naevi and neurofibromatosis.
(c)Benign neoplasm of the eye and adnexa attracts ICD-10-AM code D31.
(d)In the application of this Statement of Principles, the definition of "benign neoplasm of the eye and adnexa" is that given at paragraph 3(b) above.
Basis for determining the factors
The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that benign neoplasm of the eye and adnexa and death from benign neoplasm of the eye and adnexa can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the Military Rehabilitation and Compensation Act 2004 (the MRCA).
Factors that must be related to service
Subject to clause 7, at least one of the factors set out in clause 6 must be related to the relevant service rendered by the person.
Factors
The factor that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting benign neoplasm of the eye and adnexa or death from benign neoplasm of the eye and adnexa with the circumstances of a person’s relevant service is:
(a)for keratoacanthoma of the conjunctiva only, having sunlight exposure to the unprotected eye for at least 2250 hours while in a tropical area, or having equivalent sunlight exposure in other latitude zones, before the clinical onset of benign neoplasm of the eye and adnexa; or
(b)for papilloma of the conjunctiva only, having human papilloma virus infection at the time of the clinical onset of benign neoplasm of the eye and adnexa; or
(c)(i) for schwannoma only, having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the eye or orbit at least five years before the clinical onset of benign neoplasm of the eye and adnexa; or
(d)inability to obtain appropriate clinical management for benign neoplasm of the eye and adnexa.
Factors that apply only to material contribution or aggravation
Paragraph 6(d) applies only to material contribution to, or aggravation of, benign neoplasm of the eye and adnexa where the person’s benign neoplasm of the eye and adnexa was suffered or contracted before or during (but not arising out of) the person’s relevant service.
Inclusion of Statements of Principles
In this Statement of Principles if a relevant factor applies and that factor includes an injury or disease in respect of which there is a Statement of Principles then the factors in that last mentioned Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.
Other definitions
For the purposes of this Statement of Principles:
"cumulative equivalent dose" means the total dose of ionising radiation received by the particular organ or tissue. The formula used to calculate the cumulative equivalent dose allows doses from multiple types of ionising radiation to be combined, by accounting for their differing biological effect. The unit of equivalent dose is the sievert. For the purposes of this Statement of Principles, the calculation of cumulative equivalent dose excludes doses received from normal background radiation, but includes therapeutic radiation, diagnostic radiation, cosmic radiation at high altitude, radiation from occupation-related sources and radiation from nuclear explosions or accidents;
"death from benign neoplasm of the eye and adnexa" in relation to a person includes death from a terminal event or condition that was contributed to by the person’s benign neoplasm of the eye and adnexa;
"equivalent sunlight exposure in other latitude zones" means the cumulative hours of sunlight exposure equivalent to that specified for a tropical area, calculated by multiplying the hours of exposure in each latitude zone by the latitude weighting factor for the zone as per the latitude weighting factor schedule and adding together the result for each zone:
Latitude weighting factor schedule
Latitude zone Latitude weighting factor
a latitude between 23° 27' S and 23° 27' N 1.0
a latitude from > 23° 27' to 35° 0.75
a latitude from > 35° to 45° 0.5
a latitude from > 45° to 65° 0.25;
"human papilloma virus" means a strain of human papilloma virus capable of causing genital warts. Infection with human papilloma virus can occur without clinically obvious evidence of warts;
"ICD-10-AM code" means a number assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, 10th revision, Australian Modification (ICD-10-AM), Fifth Edition, effective date of 1 July 2006, copyrighted by the National Centre for Classification in Health, Sydney, NSW, and having ISBN 1 86487 772 3;
"relevant service" means:
(a) operational service under the VEA;
(b) peacekeeping service under the VEA;
(c) hazardous service under the VEA;
(d) warlike service under the MRCA; or
(e) non-warlike service under the MRCA;
"schwannoma" means a benign neoplasm originating from Schwann cells of the myelin sheath of neurons of peripheral nerves and comprise two types, neurilemomas and neurofibromas;
"terminal event" means the proximate or ultimate cause of death and includes:
(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function.
Application
This Instrument applies to all matters to which section 120A of the VEA or section 338 of the MRCA applies.
Date of effect
This Instrument takes effect from 30 April 2008.
Notes to Statement of Principles concerning benign neoplasm of the eye and adnexa (Instrument No. 33 of 2008)
The Statement of Principles concerning benign neoplasm of the eye and adnexa (Instrument No. 33 of 2008) in force under section 196B(2) of the Veterans’ Entitlements Act 1986, as shown in this compilation is amended as indicated in the Tables below.
Table of Instruments
| Title | Date of FRLI registration | Date of | Application, saving or |
| Statement of Principles concerning benign neoplasm of the eye and adnexa (Instrument No. 33 of 2008) | 23 April 2008 F2008L01120 | 30 April 2008 | |
| Amendment of Statement of Principles concerning benign neoplasm of the eye and adnexa (Instrument No. 75 of 2011) | 12 May 2011 F2011L00739 | 25 May 2011 |
Table of Amendments
| ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted | |
| Provision affected | How affected |
| Clause 6(c)(i) | rs. Instrument No. 75 of 2011 |
| Clause 6(c)(ii) | rep. Instrument No. 75 of 2011 |
| Clause 9 – ' "cumulative equivalent dose"…' | rs. Instrument No. 75 of 2011 |
| Clause 9 – ' "a course of therapeutic radiation"…' | rep. Instrument No. 75 of 2011 |
| Clause 9 – ' "atomic radiation"…' | rep. Instrument No. 75 of 2011 |
0
0
0